Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04181203 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Study acronym: CARLHA-2
StatusActive, Not Recruiting
PhasePhase 3
SponsorUNICANCER
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 15 of 15 sitesv9 Show 1 more changeShow less
    • Site details revised at 15 of 15 sites
  2. Eligibility criteria shortened, about 41 wordsv8 See this version in full on ClinicalTrials.gov ↗
  3. Eligibility criteria shortened, about 9 wordsv7 See this version in full on ClinicalTrials.gov ↗
  4. Re-verified, no change to tracked fieldsv6
  5. Trial status: Suspended to Recruiting Site details revised at 15 of 15 sitesv5 Show 1 more changeShow less
    • Site details revised at 15 of 15 sites
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Recruiting to Suspended Sponsor's reason: Temporary suspension since March 20 due to COVID-19 pandemic Site details revised at 15 of 15 sitesv4 Show 1 more changeShow less
    • Site details revised at 15 of 15 sites
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 10, 2019 to Jan 9, 2020 · Site details revised at 15 of 15 sites · Study title revised · 1 morev3 Show 4 more changesShow less
    • Start date changed from estimate of Dec 10, 2019 to Jan 9, 2020
    • Site details revised at 15 of 15 sites
    • Study title revised
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
UNICANCER
98 trials monitored
See 7 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
This is a multicenter, randomized, open label, phase III study comparing the efficacy and safety of apatulamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) versus concomitant prostate-bed SRT and ADT in high-risk postprostatectomy biochemically relapsed prostate cancer patients.
Trial Details
NCT Number NCT04181203
Lead Sponsor UNICANCER
Collaborators: Janssen Pharmaceutica
Conditions Prostate Cancer
Enrollment 490 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov